Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
View Patent ↗This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.
1. A gastrointestinal tissue growth promoter derivative comprising
a GLP-2 peptide of SEQ ID NO:7 or an analog or fragment thereof having gastrointestinal tissue growth promoting activity; and
a reactive entity coupled to the peptide,
the derivative being capable of covalently bonding in vivo with a functionality on a blood component.
2. A pharmaceutical composition comprising the derivative of claim 1 in combination with a pharmaceutically acceptable carrier.
3. The composition of claim 2 for the treatment of gastrointestinal disorders or diseases.
4. A method for the treatment of gastrointestinal disorders or diseases in a subject comprising administering to a subject an effective amount of the derivative of claim 1 , alone or in combination with a pharmaceutically acceptable carrier.
5. A method for the promotion of gastrointestinal tissue growth in a subject comprising administering to a subject an effective amount of the derivative of claim 1 , alone or in combination with a pharmaceutical carrier.
6. A conjugate comprising the derivative of claim 1 covalently bonded to a blood component.
7. A method for extending the in vivo half-life of a GLP-2 peptide of SEQ ID NO:7 or an analog or fragment thereof having gastrointestinal tissue growth promoting activity, the method comprising covalently bonding in vivo or ex vivo the peptide to a blood component.
8. A method for the treatment of gastrointestinal disorders or diseases in a subject comprising administering to a subject an effective amount of the conjugate of claim 6 , alone or in combination with a pharmaceutically acceptable carrier.